logo
The Best Cities To Live In, According To The Global Liveability Index

The Best Cities To Live In, According To The Global Liveability Index

Forbes17-06-2025
The release of the 2025 Global Liveability Index from the Economist Intelligence Unit (EIU) has seen a new city take the crown as the world's most liveable. After three years at the top of the rankings, Austria's capital Vienna has finally been usurped by Denmark's capital city, Copenhagen.
Welcome to the world's best city to live in. Copenhagen achieved near perfect scores across the board.
The EIU's annual index assesses 173 locations around the world, ranking their liveability based on a variety of indicators and criteria. This ranking attempts to quantify the challenges someone might face to their lifestyle in any of the given locations, to help assess which offer the best and worst living conditions.
Each city is measured across 30+ qualitative and quantitative factors in five categories described as stability, healthcare, culture and environment, education, and infrastructure. Qualitative factors are decided by a panel of expert EIU analysts and in-city contributors. Quantitative factors are based on the relative performance of a range of external data points. Each factor is then assigned a rating as acceptable, tolerable, uncomfortable, undesirable or intolerable.
The EIU Index then assigns a score to each category, which are compiled and weighted to create an easy reference 1-100 score, where 1 is intolerable and 100 is ideal.
Copenhagen has been crowned the world's most comfortable city to live in 2025, earning perfect scores for stability, education and infrastructure. Its overall Index score reached 98 of a possible 100.
Although Vienna has lost the top spot, it remains one of the great cities to live in—or just to visit.
It beats the longstanding leader, Vienna, into second place, although the Austrian capital also scored perfectly for education and infrastructure, as well as healthcare. Vienna shares second this year with Zurich, which ranked perfectly in both the education and healthcare categories. Another Swiss city, Geneva, ranked fifth overall, showcasing the dominance of Western European cities in the index with four of the top five positions.
The only city to break that European grip is Melbourne in Australia, which takes fourth spot with an overall score of 97 out of 100. The Southern Hemisphere comes into its own for the remaining top ten places with Australia's Sydney and Adelaide in sixth and ninth places respectively, Osaka in Japan in seventh and Auckland in New Zealand in eighth. Just sneaking into the top is North America's sole representative, Vancouver.
London remains the UK's most liveable city but has dropped out of the top 50 globally.
While Western European cities dominate the Index, it's notable that all the UK cities covered—London, Manchester and Edinburgh—have dropped down the rankings and sit well outside the top ten. This is due to a combination of political instability and growing civil unrest that has impacted scores. In 2025, London dropped from 45th to 54th place, Manchester from 43rd to 52nd and Edinburgh from 59th to 64th.
The reason for Vienna's fall from the top spot comes down to its declining stability score, impacted by a variety of factors including terrorism scares, one of which saw Taylor Swift's summer 2024 concert canceled.
The 2025 Global Liveability Index Top 10
Deputy industry director at EIU, Barsali Bhattacharyya commented, 'Global liveability has remained flat over the past year, and as in 2024, scores for stability have declined at a global level. Pressure on stability has led Vienna to lose its position as the most liveable city after a three-year stint. As in 2024, stability scores have declined for western Europe and the Middle East and North Africa. In this edition, they have also declined for Asia, amid intensified threats of military conflict for cities in India and Taiwan.'
While the average overall liveability score across the Index was consistent with 2024 at 76.1 out of 100, stability scores fell by 0.2 points overall. This comes amid huge global geopolitical tensions, civil unrest and a growing global housing crisis. Conversely, the Index has also seen overall gains in scores for healthcare, education and infrastructure.
There have been some very notable movements both up and down the Index in 2025. Canadian cities in particular have suffered, with Calgary dropping from fifth place in 2024 to 18th place in 2025 after a marked drop in its healthcare score. This has impacted all four Canadian cities in the Index after the well-publicized strain on the country's healthcare system thanks to a shortage of staff, among other factors. Toronto saw its ranking drop from 12th to 16th.
While those numbers don't look great, it's still important to look at them in context. Alongside the other 20 North America cities ranked, all reported the highest possible tier of liveability according to the Index's criteria, scoring above 80 out of 100. The highest U.S. city on the list was Honolulu in Hawaii, which ranked 23rd overall.
Improvements in healthcare and education have seen Middle Eastern cities like Al Khobar great improve liveability scores.
Moving up the Index, Al Khobar in Saudi Arabia's Persian Gulf saw the biggest leap, climbing 13 places from 148th to 135th thanks to improved healthcare and education. This reflects a trend across regions in the Middle East and North Africa, which saw the most significant global gains in overall liveability, largely driven by advancements in healthcare and education within cities in Saudi Arabia and the UAE.
Propping up the Index once again is war torn Damascus in Syria, which has seen no improvement in its liveability score despite the fall of ex-president Bashar al-Assad and subsequent regime change in December 2024. While this should increase its potential for improvement dramatically, the legacy of a years-long civil war will realistically take years to recover from.
Despite a regime change, years of civil war have left Damascus rooted to the bottom of the Global Liveability Index.
This is reflected in the significant jump to the second and third worst ranked cities, Tripoli in Libya and Dhakar in Bangladesh.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

High demand expected for new daily weight loss pill
High demand expected for new daily weight loss pill

Yahoo

time21 minutes ago

  • Yahoo

High demand expected for new daily weight loss pill

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially offering people with obesity a new and convenient alternative to jabs. Pharmaceutical company Eli Lilly said it expects substantial demand when the new pill is launched. Lilly said it will seek approval by international regulators as it published the results of a large study into orforglipron. The new pill is a GLP-1 agonist, a type of medication which helps lower blood sugar levels, slows the digestion of food and can reduce appetite. The manufacturer also makes Mounjaro, dubbed the King Kong of weight loss jabs. Weight loss jabs have been hailed as transformative by health leaders. But injections come with additional work for over-stretched health services so tablet forms of medication, which are expected to be cheaper and easier to use, may offer a new hope for the millions of people looking to lose weight. The new study data on orforglipron showed that people taking the drug lost an average of 12.3 kilograms while taking the drug for 72 weeks compared with those not taking the drug. Three in five (60%) of people taking the highest dose of orforglipron lost at least 10% of their body weight, while 40% lost at least 15% of their body weight, according to the study, which is to be presented to the European Association for the Study of Diabetes (EASD) Annual Meeting 2025. In addition to weight loss the people in the study also showed other health benefits, including improvements in cholesterol, blood pressure and heart disease risk. Experts highlighted how the tablet did not appear to yield the same benefits as some weight loss jabs, but said they will be more 'tolerable' for many patients. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most commonly reported side effect. The pill was assessed in a study of 3,127 adults who were obese or overweight, with a weight-related medical problem and without diabetes. 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,' said Lilly's Kenneth Custer. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These preliminary results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients. 'The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.' It comes as a separate study highlighted the potential other benefits of using GLP-1s, also known as glucagon-like peptide 1 receptor-agonists. They were initially developed as a treatment for people with type 2 diabetes and are now widely used to treat obesity and help people lose weight. The separate paper, from McGill University and the Lady Davis Institute for Medical Research at the Jewish General Hospital in Canada, examined the benefits of these drugs beyond weight loss by looking at trials which had assessed the drugs in other areas of medicine. Writing in the journal eClinicalMedicine, experts said GLP-1s may also play a role in improving liver disease; sleep apnoea; arthritis of the knee; polycystic ovary syndrome; Parkinson's disease; Alzheimer's disease and substance misuse. But they also highlighted potential safety issues linked to the drugs including potential issues with the pancreas and gall bladder. 'The therapeutic landscape for obesity and related metabolic conditions has evolved substantially with the emergence of GLP-1 RAs,' they wrote. 'These agents now play a central role not only in weight management and diabetes care but are also being investigated in a growing number of conditions, including cardiovascular, renal, hepatic, neurologic, and substance use disorders. 'As their indications expand, so must our understanding of long-term efficacy, safety, and patient-centred treatment strategies.' Sign in to access your portfolio

Genmab Announces Financial Results for the First Half of 2025
Genmab Announces Financial Results for the First Half of 2025

Yahoo

time21 minutes ago

  • Yahoo

Genmab Announces Financial Results for the First Half of 2025

August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R2 in patients with relapsed or refractory FL Rinatabart sesutecan (Rina-S®) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual Meeting Data from over 40 abstracts highlighting the depth, breadth and strength of Genmab's comprehensive epcoritamab development program presented at multiple medical conferences Genmab revenue increased 19% compared to the first six months of 2024, to $1,640 million 'In the first half of the year we continued to make progress towards our strategic priorities as we strive towards our goal of bringing our innovative therapies to additional patients in need. We further maximized the potential of our commercialized medicines with an additional sBLA submission for EPKINLY® (epcoritamab-bysp) and the launch of Tivdak® (tisotumab vedotin) in Japan. We also accelerated the development of our late-stage pipeline through both encouraging data presentations and, for Rina-S, the announcement of additional planned Phase 3 clinical trials,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Financial Performance First Half of 2025 Revenue was $1,640 million for the first six months of 2025 compared to $1,382 million for the first six months of 2024. The increase of $258 million, or 19%, was primarily driven by higher DARZALEX® and Kesimpta® royalties achieved under our collaborations with Johnson & Johnson (J&J) and Novartis Pharma AG (Novartis), respectively, and higher EPKINLY net product sales. Royalty revenue was $1,378 million in the first six months of 2025 compared to $1,111 million in the first six months of 2024, an increase of $267 million, or 24%. The increase in royalties was driven by higher net sales of DARZALEX and Kesimpta. Net sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.) by J&J were $6,776 million in the first six months of 2025 compared to $5,570 million in the first six months of 2024, an increase of $1,206 million or 22%. Total costs and operating expenses were $1,092 million in the first six months of 2025 compared to $1,030 million in the first six months of 2024. The increase of $62 million, or 6%, was driven by the expansion of our product pipeline, including advancement of Rina-S, the continued development of Genmab's broader organizational capabilities as well as profit-sharing amounts payable to AbbVie Inc. (AbbVie) related to EPKINLY sales. Operating profit was $548 million in the first six months of 2025 compared to $352 million in the first six months of 2024. Net financial items resulted in income of $119 million for the first six months of 2025 compared to $204 million in the first six months of 2024. The decrease was primarily due to a decrease in foreign exchange impacts driven by the change in functional currency of Genmab A/S on January 1, 2025, as well as a decrease in interest income for the first six months of 2025 compared to the first six months of 2024 related to average lower cash balances. OutlookGenmab is updating its revenue and operating profit guidance for 2025. The improved guidance is driven by higher total royalty revenues from DARZALEX. 2025 FULL YEAR OUTLOOK (USD million) Revised Guidance Revised Mid-Point Previous Guidance Guidance Mid-Point Revenue 3,500 - 3,700 3,600 3,340 - 3,660 3,500 Royalties 2,945 - 3,090 3,017 2,785 - 3,015 2,900 Net product sales/Collaboration revenue* 425 - 465 445 415 - 460 438 Milestones/Reimbursement revenue 130 - 145 138 140 - 185 162 Gross profit** 3,280 - 3,460 3,370 3,120 - 3,420 3,270 Operating expenses** (2,055) - (2,225) (2,140) (2,055) - (2,225) (2,140) Operating profit 1,055 - 1,405 1,230 895 - 1,365 1,130 Net Product Sales and Collaboration Revenue consists of EPKINLY Net Product Sales in the U.S. and Japan and Tivdak (Genmab's share of net profits) in the U.S. and Net Product Sales in Japan Operating Expenses Range excludes Cost of Product Sales Range, which is included in Gross Profit Range Other MattersBoth the functional currency of the Genmab A/S legal entity and the presentation currency of the condensed consolidated financials statements have been changed from DKK to USD effective January 1, 2025. The change in functional currency has been implemented with prospective effect. The change in presentation currency has been implemented with retrospective effect. Comparative figures for prior periods have been restated accordingly. Conference CallGenmab will hold a conference call to discuss the results for the first half of 2025 today, Thursday, August 7, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN: A live and archived webcast of the call and relevant slides will be available at ContactMarisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E: mmp@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ *sBLA = supplemental Biologics License Application, FDA = U.S. Food and Drug Administration, R2 = rituximab and lenalidomide, FL = follicular lymphoma, ASCO = American Society of Clinical Oncology The Interim Report contains forward looking statements. The words 'believe,' 'expect,' 'anticipate,' 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in the Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®; HexElect® and KYSO®; ProfoundBio™ and Rina-S® are trademarks of ProfoundBio, US, Co. and ProfoundBio (Suzhou) Co., Ltd. Tivdak® is a trademark of Seagen Inc.; EPCORE®, EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd.; Kesimpta® and Sensoready® are trademarks of Novartis AG or its affiliates; DARZALEX®, DARZALEX FASPRO®, RYBREVANT®, TECVAYLI® and TALVEY® are trademarks of Johnson & Johnson; TEPEZZA® is a trademark of Horizon Therapeutics Ireland DAC. Download the full Interim Report for the First Half of 2025 on attachment or at CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SCarl Jacobsens Vej 302500 Valby Denmark Attachment 070825_CA40_Genmab Interim Report H1 2025Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Avidity (RNA) Gets 26% Jump on Potential Takeover
Avidity (RNA) Gets 26% Jump on Potential Takeover

Yahoo

timean hour ago

  • Yahoo

Avidity (RNA) Gets 26% Jump on Potential Takeover

We recently published . Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Wednesday. Avidity Biosciences rallied for a third day on Wednesday, jumping 26.14 percent to close at $48.26 as investors gobbled up shares following reports that it received an acquisition bid from Swiss drugmaker Novartis AG (NYSE:NVS). A report by the Financial Times, citing people privy to the matter, said that Novartis AG (NYSE:NVS) offered Avidity Biosciences, Inc. (NASDAQ:RNA) to acquire the company, in line with the former's plans to boost its pipeline of medicines targeting rare genetic disorders. Meanwhile, the report said that Avidity Biosciences, Inc. (NASDAQ:RNA) was mulling over the offer, although the talks could still collapse as other companies have emerged with separate takeover offers. Late last month, Avidity Biosciences, Inc. (NASDAQ:RNA) secured a Breakthrough Therapy designation from the Food and Drug Administration for its del-zota treatment for Duchenne muscular dystrophy (DMD) in patients with DMD44. DMD is a rare genetic condition characterized by progressive muscle damage and weakness due to the loss of dystrophin protein that typically starts at a young age. Del-zota, on the other hand, was designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. While we acknowledge the potential of RNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store